# US 11,897,862 B2 · IKAROS zinc finger family degraders and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,897,862 B2
- Document ID: US11897862B2
- Status: Granted
- Kind: B2
- Application number: 18/297,316
- Filed: 2023-04-07
- Published: 2023-09-21
- Granted: 2024-02-13
- Earliest claimed: 2022-03-17
- Assignees: Gilead Sciences, Inc.
- Applicants: Gilead Sciences, Inc.
- Inventors: Gayatri Balan; Peter A. Blomgren; Chen Chen; Julian A. Codelli; Zhimin Du; Musong Kim; Dorothée Saddier Axe; Gregg M. Schwarzwalder; Rhiannon Thomas-Tran; Michael T. Tudesco; Chandrasekar Venkataramani; William J. Watkins; Brian M. Weist; Suet C. Yeung; Helen Yu
- Web page: https://patentgrep.com/patent/US11897862B2

## CPC

- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- A61P 35/00: Antineoplastic agents
- C07D 401/14: containing three or more hetero rings
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07D 409/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D 493/08: Bridged systems
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.

## Claims

### Claim 1

A compound of the formula:
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound is

### Claim 3 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound is

### Claim 4 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound is

### Claim 5 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound is

### Claim 6 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound is

### Claim 7 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound is

### Claim 8 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound is

### Claim 9 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound is

### Claim 10 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound is